SCHEMBL2607446

SCHEMBL2607446

CS(=O)(=O)c1ccc(-c2nc3cncnc3n2-c2ccc(Oc3ccccc3)cc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 11/20 0.51
USP2 O75604 11/20 0.51
CYP3A4 P08684 10/20 0.51
CASP1 P29466 1/20 0.51
CASP7 P55210 1/20 0.51
CYP2C19 P33261 6/20 0.49
MAPK1 P28482 4/20 0.49
CYP2D6 P10635 2/20 0.49
CYP2C9 P11712 6/20 0.48
ALDH1A1 P00352 5/20 0.48
HSD17B10 Q99714 3/20 0.48
TSHR P16473 4/20 0.46
ALOX15 P16050 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
GLA P06280 1/20 0.43
ATR Q13535 1/20 0.43
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
PTGS2 P35354 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2607449 0.90 CYP1A2 (0.53) CYP1A2USP2CYP3A4CASP1CASP7
SCHEMBL2607452 0.86 PTGS2 (0.49) CYP1A2USP2CYP3A4CASP1CASP7
SCHEMBL2607427 0.85 CYP1A2 (0.48) CYP1A2USP2CYP3A4CASP1CASP7
SCHEMBL2607669 0.85 CYP1A2 (0.48) CYP1A2USP2CYP3A4CASP1CASP7
SCHEMBL2607565 0.85 CYP1A2 (0.48) CYP1A2USP2CYP3A4CASP1CASP7
SCHEMBL2607311 0.85 CYP1A2 (0.45) CYP1A2USP2CYP3A4CASP1CASP7
SCHEMBL3439922 0.83 ATR (0.47) ALDH1A1ATRPTGS2
SCHEMBL2602393 0.81 PTGS2 (0.57) ALDH1A1ATRPTGS2
SCHEMBL2602441 0.81 PTGS2 (0.43) PTGS2
SCHEMBL2607432 0.79 CYP3A4 (0.41) CYP1A2USP2CYP3A4CASP1CASP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095027-A1 SYNTHESIS AND ANTI-PROLIFERATIVE EFFECT OF BENZIMIDAZOLE DERIVATIVES SPELMAN COLLEGE (US) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095027-A1 SYNTHESIS AND ANTI-PROLIFERATIVE EFFECT OF BENZIMIDAZOLE DERIVATIVES TYMP, MKI67, CCNI CYP1A2 1466/4885USP2 4741/4885CYP3A4 641/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.